Anaplastic Large Cell Lymphoma Withdrawn Phase 2 Trials for Rituximab (DB00073)

Also known as: Lymphomas, Anaplastic Large-Cell / Anaplastic large-cell lymphoma / Large cell (Ki-1+) lymphoma / Lymphoma, Large-Cell, Anaplastic / Anaplastic large cell lymphoma, CD30-positive

IndicationStatusPhase
DBCOND0028602 (Anaplastic Large Cell Lymphoma)Withdrawn2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00310128Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's LymphomaTreatment